Impact of switching from bisphosphonates to denosumab, teriparatide, or romosozumab in patients with postmenopausal osteoporosis: a case–control study
Significant BMD increases were observed in the LS for all groups, in the TH for the ROMO and DMAb groups, and in the FN for the ROMO group. ROMO showed the most substantial BMD improvements following BP therapy.
Authors
- Yuki Etani (ORCID: https://orcid.org/0000-0001-5741-5969)
- Takaaki Noguchi (ORCID: https://orcid.org/0000-0001-9938-6780)
- Tomonori Kobayakawa
- Kosuke Ebina (ORCID: https://orcid.org/0000-0002-2426-1024)
- Seiji Okada (ORCID: https://orcid.org/0000-0002-5107-8209)
- Shin‐ichiro Ohmura (ORCID: https://orcid.org/0000-0001-8651-4149)
- Ken Nakata (ORCID: https://orcid.org/0000-0002-4086-4984)
- Toshitaka Yukishima (ORCID: https://orcid.org/0000-0003-2265-6724)
Institutions
- Osaka University of Health and Sport Sciences (JP)
- Seirei Hamamatsu General Hospital (JP)
- The University of Osaka (JP)
Publication Details
- Journal
- Osteoporosis International
- Published
- 2025-01-16
- DOI
- https://doi.org/10.1007/s00198-025-07386-4
- Citations
- 7
- Primary Topic
- Bone health and treatments
- Type
- article
- Field-Weighted Citation Impact
- 7.32
Funders
- Osaka University